NATCO Pharma soars on receiving USFDA approval for Lansoprazole Capsules

19 Dec 2012 Evaluate

NATCO Pharma is currently trading at Rs. 492.65, up by 24.60 points or 5.26% from its previous closing of Rs. 467.40 on the BSE.

The scrip opened at Rs. 477.45 and has touched a high and low of Rs. 496.00 and Rs. 477.45 respectively. So far 50,000 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 496.00 on 10-Dec-2012 and a 52 week low of Rs. 223.50 on 20-Dec-2011.

Last one week high and low of the scrip stood at Rs. 476.70 and Rs. 462.00 respectively. The current market cap of the company is Rs. 1,532 crore.

The promoters holding in the company stood at 57.05% while Institutions and Non-Institutions held 17.88% and 25.07% respectively.

NATCO Pharma has received approval from the US Food & Drug Administration (USFDA), of its Abbreviated New Drug Application (ANDA) for Lansoprazole Delayed Release Capsules, USP, 15 mg and 30 mg for the prescription market. The shipments of this product will commence immediately.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets. The company began its operations in 1984 in Andhra Pradesh.

Natco Pharma Share Price

933.60 -15.25 (-1.61%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×